In patients with acute pancreatitis, which early severity scoring system (e.g., BISAP versus APACHE II) provides the most accurate prediction of in‑hospital mortality? | Rounds In patients with acute pancreatitis, which early severity scoring system (e.g., BISAP versus APACHE II) provides the most accurate prediction of in‑hospital mortality? | Rounds
Loading...

In patients with acute pancreatitis, which early severity scoring system (e.g., BISAP versus APACHE II) provides the most accurate prediction of in‑hospital mortality?

Medical Advisory Board
All articles are reviewed for accuracy by our Medical Advisory Board.

Educational purpose only · Not a substitute for professional judgment or the full text of guidelines and labels.

Article Review Status
Submitted
Under Review
Approved

Last updated: July 24, 2026 · View editorial policy

Early Severity Scoring Systems for In-Hospital Mortality in Acute Pancreatitis

Early bedside risk stratification in acute pancreatitis shows broadly similar prognostic discrimination between the BISAP score and APACHE II. In a large population-based derivation/validation study, APACHE II showed a slightly higher AUC for in-hospital mortality than BISAP (0.83 vs 0.82). [1]

Most Accurate System Based on Available Discrimination Data

  • APACHE II demonstrated higher discrimination for in-hospital mortality than BISAP in the validation cohort using AUC (APACHE II AUC 0.83 vs BISAP AUC 0.82). [1]
  • BISAP showed strong but slightly lower discrimination for in-hospital mortality in the same validation cohort. [1]

Medication Selection Algorithm

Not applicable.

Key Evidence Supporting This Recommendation

  • Population-based validation (BISAP vs APACHE II):
  • BISAP AUC 0.82 (95% CI 0.79–0.84). [1]
  • APACHE II AUC 0.83 (95% CI 0.80–0.85). [1]

  • BISAP diagnostic performance (systematic review/meta-analysis):

  • BISAP ≥3 for mortality:
    • Pooled sensitivity 56% (95% CI 53%–60%). [2]
    • Pooled specificity 91% (95% CI 90%–91%). [2]

Monotherapy vs Combination Therapy

Not applicable.

Important Clarifications and Nuances

  • BISAP is constructed from variables available early (within the first 24 hours) and includes blood urea nitrogen (BUN) >25 mg/dL, impaired mental status, SIRS, age >60 years, and pleural effusion. [1]
  • In practice, BISAP’s high specificity can improve “rule-in” of risk, while the moderate sensitivity limits “rule-out” performance for mortality. [2]

Treatment Initiation Thresholds

Risk scores do not substitute for clinical escalation based on physiologic deterioration.

  • BISAP threshold most commonly used in the mortality meta-analysis: BISAP ≥3. [2]
  • BISAP risk stratification is based on presence/absence of early predictors in the first 24 hours. [1]

Common Pitfalls to Avoid

  • False reassurance from incomplete sensitivity: BISAP’s pooled sensitivity for mortality at BISAP ≥3 is 56%, so clinically important deterioration may be missed if mortality risk is treated as “low” based solely on the score. [2]
  • Overreliance on discrimination without calibration: AUC comparisons do not guarantee accurate prediction of absolute mortality risk across settings. [1]

Target Outcomes

  • Primary target outcome for these scoring systems: in-hospital mortality. [1]

Related Questions